Merck Exercised the Option for the Global Rights of Abbisko Therapeutics’s Pimicotinib
Press Releases
Abbisko  
April 1, 2025

Merck Exercised the Option for the Global Rights of Abbisko Therapeutics’s Pimicotinib

SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021),

avatar profile Olean Times Herald

Olean Times Herald


Local & Social